跳至主要内容
临床试验/NCT02265159
NCT02265159Unknown2 期

Intervention Trial Evaluating Focal Therapy Using High Intensity Focused Ultrasound for the Treatment of Prostate Cancer

University of Zurich2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2014年5月最近更新:
适应症

试验速览

阶段
2 期
入组人数
100
试验地点
2
主要终点
Oncological safety

研究概览

简要总结

The investigators aim to evaluate cancer control, genitourinary, rectal and overall health-related quality of life outcomes and effectiveness of focal therapy for localised prostate cancer using High Intensity Focused Ultrasound (HIFU).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
40 Years 至 99 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Histologically proven prostate cancer on trans-rectal or transperineal template prostate biopsies
  • Template biopsy:
  • unilateral disease (Gleason ≤4+3)
  • bilateral disease: presence of clinically significant cancer in both sides (Gleason ≤4+3) OR clinically insignificant disease with a burden of >50% of biopsy cores taken on that side, OR bilateral clinically insignificant disease and <50% of biopsy cores positive on any one side but with dominant disease burden on one side
  • Stage T1-T2cN0M0 disease, as determined by local guidelines (radiological T3a permitted)
  • Serum PSA ≤15
  • Life expectancy of ≥10 years
  • Signed informed consent by patient
  • An understanding of the German language sufficient to understand written and verbal information about the trial and consent process

排除标准

  • Men who have had androgen suppression/hormone treatment within the previous 12 months for their prostate cancer
  • Men with evidence of metastatic disease or nodal disease outside the prostate on bone scan or cross-sectional imaging
  • Men with an inability to tolerate a transrectal ultrasound
  • Men with latex allergies as the HIFU probe is covered with a latex condom sheath prior to insertion into the back passage
  • Men who have undergone prior significant rectal surgery preventing insertion of trans-rectal HIFU probe (decided on the type of surgery in individual cases)
  • Men who have had previous HIFU, cryosurgery, thermal or microwave therapy to the prostate.
  • Men who have undergone a Transurethral Resection of the Prostate (TURP) for symptomatic lower urinary tract symptoms within 6 months. These patients may be included within the trial if deferred from consenting and screening until at least 6 months following the TURP.
  • Men not fit for major surgery as assessed by a Consultant Anaesthetist
  • Men unable to have pelvic MRI scanning (severe claustrophobia, permanent cardiac pacemaker, metallic implant etc likely to contribute significant artefact to images)
  • Presence of metal implants/stents in the urethra
  • Presence of prostatic calcification and cysts (on transrectal ultrasound) whose location will interfere with effective delivery of HIFU therapy
  • Men with renal impairment with a glomerular filtration rate of <35ml/min (unable to tolerate Gadolinium dynamic contrast enhanced MRI).

结局指标

主要结局

Oncological safety

时间窗: 36 months

To determine the proportion of men who are free of clinically significant prostate cancer in the treated area AND are free of clinically significant prostate cancer in the untreated area 36 months after focal therapy using HIFU

次要结局

  • Biochemical failure(36 months)
  • Health care costs(36 months)
  • Lower urinary tract symptoms(36 months)
  • Sensitivity and specificity of MRI imaging(36 months)
  • Orgasmic function(36 months)
  • Sexual function(36 months)
  • Anxiety(36 months)
  • Bowel function(36 months)
  • Secondary intervention(36 months)
  • Quality of life(36 months)
  • General histological outcome(36 months)
  • Erectile function(36 months)
  • Continence(36 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Daniel Eberli

PD Dr. med. PhD

University of Zurich

研究点 (2)

Loading locations...

相似试验

Intervention Trial Evaluating Focal Therapy Using... | 临床试验